Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avi BioPharma, a developer of RNA-based drugs, has appointed Christopher Henney and Kathleen Behrens to its board of directors.
Subscribe to our email newsletter
Dr Henney has been one of the leaders and founders of the US biotechnology industry since 1980. Dr Henney co-founded three publicly held US biotechnology companies: Immunex Corporation in 1980, Icos in 1990, and Dendreon in 1997.
Dr Henney is currently chairman of Oncothyreon and vice-chairman of Cyclacel.
Dr Behrens served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and she was chair of PCAST’s subcommittee on personalized medicine.
Dr Behrens was instrumental in the founding of several biotechnology companies including Protein Design Labs, and Cor Therapeutics, and more recently was a director of Abgenix.
Leslie Hudson, president and CEO of Avi BioPharma, said: “We are very pleased to have experienced industry leaders of the stature of Kathy and Chris join our board of directors. Their insight and guidance will be invaluable to Avi as we continue to advance our promising RNA-based drugs.”